13F Holdings
中文EN

TVRD Tvardi Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1346830 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.7%
TTM EPS YoY64.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-123.1%
ROA-85.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets34.3%
Debt / equity0.00x
Current ratio2.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$7.14M$20.97M$41.87M$23.03M
Cost of revenue————$0
Gross profit————$23.03M
R&D expense$18.01M$23.65M$108.51M$91.88M$82.70M
SG&A expense$8.74M$4.46M$27.78M$30.26M$29.41M
Operating income-$26.75M-$28.11M-$121.50M-$87.53M-$89.08M
Pretax income—-$71.27M-$118.51M-$85.47M-$88.44M
Income tax$0$0$0$0$0
Net income-$18.21M-$29.40M-$118.51M-$85.47M-$88.44M
EBITDA-$26.65M-$28.01M-$121.24M-$87.29M-$88.83M
EPS (basic)-2.46-11.42-26.26-19.12-1.74
EPS (diluted)-3.26-11.42-26.26-19.12-1.74
Dividends declared per share0.00————
Weighted avg. shares (diluted)7.78M2.57M4.51M4.47M50.72M
Balance sheet
Cash & equivalents$20.73M$31.61M$22.92M$64.15M$13.86M
Short-term investments$10.08M———$153.58M
Receivables—$407,000$2.77M$3.26M—
Inventory—$900,000$2.82M$2.38M$2.58M
Current assets$31.54M$31.69M$116.16M$168.91M$173.29M
PP&E, net$52,000$84,000$3.32M$426,000$631,000
Intangibles$322,000$385,000———
Total assets$32.07M$35.20M$125.84M$182.24M$247.06M
Current liabilities$11.04M$10.37M$25.59M$23.46M$17.62M
Total liabilities$11.13M$40.83M$68.76M$23.46M$19.53M
Shareholders' equity$20.95M-$91.13M-$62.06M$158.78M$227.52M
Shares outstanding9.38M2.57M4.54M53.80M53.48M
Cash flow statement
Operating cash flow-$23.50M-$18.30M-$92.08M-$78.73M-$60.09M
Capital expenditure—$1.05M$2.38M$43,000$39,000
Free cash flow—-$19.35M-$94.45M-$78.77M-$60.13M
Investing cash flow-$10.08M$48.74M$43.46M$128.71M-$4.75M
Financing cash flow$22.70M$27.00M$38.15M$311,000$46.61M
Depreciation & amortization$95,000$95,000$259,000$248,000$248,000
Stock-based compensation$1.40M$319,000$13.73M$17.73M$20.79M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.